3 Hrs
Source:
الاقتصادية
Source: الاقتصادية
3 Hrsالاقتصادية
Source: الاقتصادية
3 HrsReady to play
Ready to play
Amgen’s sales rose 8% in the third quarter, driven by demand for its cholesterol drug Repatha, cancer treatment Imdelltra and rare-disease drug Uplizna. Revenue reached $10.4 billion, while adjusted earnings rose 14% to $6.45 per share, exceeding analysts’ expectations of $5.79. The company raised its full-year guidance for adjusted earnings to $22.90–$23.70 per share and for revenue to $38.9–$39.7 billion.
Notice: This Is an AI-Generated Summary
Comments (0)